Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding: 2023-2024

Historic Shares Outstanding for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $25.9 million.

  • Contineum Therapeutics' Shares Outstanding rose 13.39% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 13.39%. This contributed to the annual value of $25.9 million for FY2024, which is 62.54% up from last year.
  • Per Contineum Therapeutics' latest filing, its Shares Outstanding stood at $25.9 million for FY2024, which was up 62.54% from $15.9 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Shares Outstanding ranged from a high of $25.9 million in FY2024 and a low of $15.9 million during FY2023.
  • Its 2-year average for Shares Outstanding is $20.9 million, with a median of $20.9 million in 2023.
  • Data for Contineum Therapeutics' Shares Outstanding shows a peak YoY surged of 62.54% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Shares Outstanding stood at $15.9 million in 2023, then surged by 62.54% to $25.9 million in 2024.